Effect of Changing Breast Cancer Incidence Rates on the Calibration of the Gail Model
- 10 May 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (14) , 2411-2417
Abstract
Purpose: The Gail model combines relative risks (RRs) for five breast cancer risk factors with age-specific breast cancer incidence rates and competing mortality rates from the Surveillance, Epidemiology, and End Results (SEER) program from 1983 to 1987 to predict risk of invasive breast cancer over a given time period. Motivated by changes in breast cancer incidence during the 1990s, we evaluated the model's calibration in two recent cohorts. Methods: We included white, postmenopausal women from the National Institutes of Health (NIH) –AARP Diet and Health Study (NIH-AARP, 1995 to 2003), and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO, 1993 to 2006). Calibration was assessed by comparing the number of breast cancers expected from the Gail model with that observed. We then evaluated calibration by using an updated model that combined Gail model RRs with 1995 to 2003 SEER invasive breast cancer incidence rates. Results: Overall, the Gail model significantly underpredicted the number of invasive breast cancers in NIH-AARP, with an expected-to-observed ratio of 0.87 (95% CI, 0.85 to 0.89), and in PLCO, with an expected-to-observed ratio of 0.86 (95% CI, 0.82 to 0.90). The updated model was well-calibrated overall, with an expected-to-observed ratio of 1.03 (95% CI, 1.00 to 1.05) in NIH-AARP and an expected-to-observed ratio of 1.01 (95% CI: 0.97 to 1.06) in PLCO. Of women age 50 to 55 years at baseline, 13% to 14% had a projected Gail model 5-year risk lower than the recommended threshold of 1.66% for use of tamoxifen or raloxifene but ≥ 1.66% when using the updated model. The Gail model was well calibrated in PLCO when the prediction period was restricted to 2003 to 2006. Conclusion: This study highlights that model calibration is important to ensure the usefulness of risk prediction models for clinical decision making.Keywords
This publication has 20 references indexed in Scilit:
- Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer ChemopreventionJNCI: Journal of the National Cancer Institute, 2003
- Design and Serendipity in Establishing a Large Cohort with Wide Dietary Intake DistributionsAmerican Journal of Epidemiology, 2001
- Validation of the Gail et al. Model of Breast Cancer Risk Prediction and Implications for ChemopreventionJNCI: Journal of the National Cancer Institute, 2001
- Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast CancerJNCI: Journal of the National Cancer Institute, 1999
- Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer IncidenceJNCI: Journal of the National Cancer Institute, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States)Cancer Causes & Control, 1994
- Validation of a Breast Cancer Risk Assessment Model in Women With a Positive Family HistoryJNCI: Journal of the National Cancer Institute, 1994
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989